| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 36.25M | 15.35M | 31.18M | 34.29M | 18.66M | 22.39M | 197.58M | 1.6B | 556.38M | 682.16M |
| Revenue Growth % | 0.18% | -0.58% | 1.03% | 0.1% | -0.46% | 0.2% | 7.83% | 7.09% | -0.65% | 0.23% |
| Cost of Goods Sold | 162.64M | 237.94M | 0 | 0 | 113.84M | 0 | 0 | 902.64M | 343.77M | 202.74M |
| COGS % of Revenue | 4.49% | 15.5% | - | - | 6.1% | - | - | 0.56% | 0.62% | 0.3% |
| Gross Profit | -126.39M | -222.59M | 31.18M | 34.29M | -95.18M | 22.39M | 197.58M | 696.31M | 212.61M | 479.42M |
| Gross Margin % | -3.49% | -14.5% | 1% | 1% | -5.1% | 1% | 1% | 0.44% | 0.38% | 0.7% |
| Gross Profit Growth % | -9.06% | -0.76% | 1.14% | 0.1% | -3.78% | 1.24% | 7.83% | 2.52% | -0.69% | 1.25% |
| Operating Expenses | 193.49M | 284.47M | 202.89M | 208.21M | 148.26M | 439.11M | 1.88B | 1.34B | 779.13M | 728.35M |
| OpEx % of Revenue | 5.34% | 18.53% | 6.51% | 6.07% | 7.94% | 19.61% | 9.54% | 0.84% | 1.4% | 1.07% |
| Selling, General & Admin | 30.84M | 46.53M | 34.45M | 34.41M | 34.42M | 145.29M | 298.36M | 488.69M | 468.95M | 337.19M |
| SG&A % of Revenue | 0.85% | 3.03% | 1.11% | 1% | 1.84% | 6.49% | 1.51% | 0.31% | 0.84% | 0.49% |
| Research & Development | 162.64M | 237.94M | 168.44M | 173.8M | 113.84M | 747.03M | 2.53B | 1.24B | 737.5M | 391.17M |
| R&D % of Revenue | 4.49% | 15.5% | 5.4% | 5.07% | 6.1% | 33.37% | 12.83% | 0.77% | 1.33% | 0.57% |
| Other Operating Expenses | -120K | -31K | 67K | 108K | -13K | -453.21M | -948.71M | -382.92M | -427.32M | 0 |
| Operating Income | -157.24M | -269.11M | -171.71M | -173.92M | -120.58M | -416.72M | -1.69B | -644.74M | -566.51M | -248.93M |
| Operating Margin % | -4.34% | -17.53% | -5.51% | -5.07% | -6.46% | -18.61% | -8.54% | -0.4% | -1.02% | -0.36% |
| Operating Income Growth % | -0.88% | -0.71% | 0.36% | -0.01% | 0.31% | -2.46% | -3.05% | 0.62% | 0.12% | 0.56% |
| EBITDA | -151.25M | -260.61M | -161.89M | -165.76M | -114.78M | -411.83M | -1.67B | -615.68M | -525.29M | -200.44M |
| EBITDA Margin % | -4.17% | -16.97% | -5.19% | -4.83% | -6.15% | -18.4% | -8.47% | -0.39% | -0.94% | -0.29% |
| EBITDA Growth % | -0.91% | -0.72% | 0.38% | -0.02% | 0.31% | -2.59% | -3.06% | 0.63% | 0.15% | 0.62% |
| D&A (Non-Cash Add-back) | 5.98M | 8.51M | 9.82M | 8.16M | 5.8M | 4.88M | 12.66M | 29.05M | 41.23M | 48.5M |
| EBIT | -156.7M | -267M | -169.7M | -172.56M | -119.08M | -403.11M | -1.69B | -633.77M | -528.62M | -156.54M |
| Net Interest Income | -241K | -12.96M | -14.07M | -13.61M | -12.1M | -15.14M | -21.13M | -19.88M | -14.42M | -20.07M |
| Interest Income | 0 | 0 | 0 | 0 | 1.51M | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 241K | 12.96M | 14.07M | 12.19M | 13.61M | 15.14M | 21.13M | 19.88M | 14.42M | 20.07M |
| Other Income/Expense | 299K | -10.85M | -12.06M | -10.83M | -12.11M | -1.54M | -27.96M | -8.91M | 23.48M | 72.32M |
| Pretax Income | -156.94M | -279.97M | -183.77M | -184.75M | -132.69M | -418.26M | -1.71B | -653.65M | -543.03M | -176.62M |
| Pretax Margin % | -4.33% | -18.24% | -5.89% | -5.39% | -7.11% | -18.68% | -8.68% | -0.41% | -0.98% | -0.26% |
| Income Tax | 0 | 2.32M | 0 | 1.36M | 0 | 0 | 29.21M | 4.29M | 2.03M | 10.88M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 0.98% | 1% | 1.02% | 1.01% | 1% | 1.06% |
| Net Income | -156.94M | -279.97M | -183.77M | -184.75M | -130.1M | -418.26M | -1.74B | -657.94M | -545.06M | -187.5M |
| Net Margin % | -4.33% | -18.24% | -5.89% | -5.39% | -6.97% | -18.68% | -8.83% | -0.41% | -0.98% | -0.27% |
| Net Income Growth % | -0.89% | -0.78% | 0.34% | -0.01% | 0.3% | -2.21% | -3.17% | 0.62% | 0.17% | 0.66% |
| Net Income (Continuing) | -156.94M | -279.97M | -183.77M | -184.75M | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M | -187.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -11.97 | -20.68 | -12.56 | -9.99 | -5.40 | -7.43 | -23.44 | -8.42 | -5.41 | -1.23 |
| EPS Growth % | -0.63% | -0.73% | 0.39% | 0.2% | 0.46% | -0.38% | -2.15% | 0.64% | 0.36% | 0.77% |
| EPS (Basic) | -11.97 | -20.68 | -12.56 | -9.99 | -5.40 | -7.43 | -23.44 | -8.42 | -5.41 | -1.23 |
| Diluted Shares Outstanding | 13.11M | 13.54M | 14.63M | 18.49M | 24.1M | 57.55M | 74.4M | 78.18M | 100.77M | 152.19M |
| Basic Shares Outstanding | 13.11M | 13.54M | 14.63M | 18.49M | 24.1M | 57.55M | 74.4M | 78.18M | 100.77M | 152.19M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 287.26M | 287.83M | 203.31M | 119.28M | 97.25M | 1.25B | 2.16B | 1.7B | 1.14B | 1.13B |
| Cash & Short-Term Investments | 230.66M | 144.35M | 106.31M | 70.15M | 78.82M | 711.05M | 1.52B | 1.34B | 568.5M | 923.12M |
| Cash Only | 93.11M | 144.35M | 106.31M | 70.15M | 78.82M | 553.4M | 1.52B | 1.34B | 568.5M | 530.23M |
| Short-Term Investments | 137.55M | 0 | 0 | 0 | 0 | 157.65M | 0 | 0 | 0 | 392.89M |
| Accounts Receivable | 2.32M | 233K | 0 | 0 | 7.5M | 262.01M | 454.99M | 82.38M | 297.24M | 108.28M |
| Days Sales Outstanding | 23.36 | 5.54 | - | - | 146.69 | 4.27K | 840.53 | 18.8 | 195 | 57.94 |
| Inventory | 0 | 15.74M | 13.09M | 11.97M | 0 | 0 | 0 | 36.68M | 41.7M | 8.75M |
| Days Inventory Outstanding | - | 24.14 | - | - | - | - | - | 14.83 | 44.27 | 15.75 |
| Other Current Assets | 41.31M | 20.65M | 19.84M | 3.19M | 7.32M | 103.54M | 56.11M | 86.68M | 166.15M | 32.51M |
| Total Non-Current Assets | 98.78M | 106.47M | 99.18M | 88.7M | 75.71M | 334.28M | 421.63M | 555.29M | 653.6M | 431.48M |
| Property, Plant & Equipment | 32.34M | 40.18M | 35.99M | 28.43M | 11.45M | 179.95M | 228.7M | 400.49M | 490.99M | 300M |
| Fixed Asset Turnover | 1.12x | 0.38x | 0.87x | 1.21x | 1.63x | 0.12x | 0.86x | 3.99x | 1.13x | 2.27x |
| Goodwill | 53.06M | 51.67M | 53.56M | 51.97M | 51.15M | 135.38M | 131.48M | 126.33M | 127.45M | 107.48M |
| Intangible Assets | 10.79M | 9.22M | 7.87M | 6.54M | 5.58M | 5.72M | 4.77M | 0 | 0 | 0 |
| Long-Term Investments | 1.54M | 4.59M | 890K | 958K | 410K | 0 | 1.65M | 1.66M | 0 | 0 |
| Other Non-Current Assets | 2.58M | 5.39M | 1.76M | 1.77M | 7.53M | 13.22M | 56.69M | 28.47M | 35.16M | 24M |
| Total Assets | 386.04M | 394.3M | 302.49M | 207.98M | 172.96M | 1.58B | 2.58B | 2.26B | 1.8B | 1.56B |
| Asset Turnover | 0.09x | 0.04x | 0.10x | 0.16x | 0.11x | 0.01x | 0.08x | 0.71x | 0.31x | 0.44x |
| Asset Growth % | 0.4% | 0.02% | -0.23% | -0.31% | -0.17% | 8.15% | 0.63% | -0.12% | -0.2% | -0.13% |
| Total Current Liabilities | 76.49M | 66.41M | 73.67M | 45.54M | 25.8M | 579.67M | 2.39B | 2.46B | 1.64B | 1.15B |
| Accounts Payable | 11.89M | 5.68M | 5.61M | 9.3M | 2.91M | 54.33M | 127.05M | 216.52M | 132.61M | 41.58M |
| Days Payables Outstanding | 26.68 | 8.72 | - | - | 9.33 | - | - | 87.55 | 140.8 | 74.86 |
| Short-Term Debt | 395K | 0 | 0 | 0 | 0 | 0 | 0 | 324.88M | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 18.49M | 23.34M | 31.25M | 16.6M | 12.44M | 29.61M | 74.48M | 982.62M | 917.36M | 279.95M |
| Current Ratio | 3.76x | 4.33x | 2.76x | 2.62x | 3.77x | 2.15x | 0.90x | 0.69x | 0.70x | 0.98x |
| Quick Ratio | 3.76x | 4.10x | 2.58x | 2.36x | 3.77x | 2.15x | 0.90x | 0.68x | 0.67x | 0.97x |
| Cash Conversion Cycle | - | 20.96 | - | - | - | - | - | -53.92 | 98.47 | -1.17 |
| Total Non-Current Liabilities | 16.88M | 333.44M | 330.55M | 330.37M | 333.18M | 375.6M | 538.11M | 432.81M | 879.28M | 1.03B |
| Long-Term Debt | 0 | 316.34M | 317.76M | 319.19M | 320.61M | 322.04M | 323.46M | 166.47M | 168.02M | 169.68M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 40.08M | 0 | 31.24M | 55.92M | 53.73M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 12.7M | 14.6M | 10.29M | 8.69M | 10.07M | 13.48M | 42.12M | 55.7M | 33.13M | 359.61M |
| Total Liabilities | 93.37M | 399.85M | 404.23M | 375.91M | 358.97M | 955.27M | 2.93B | 2.89B | 2.51B | 2.18B |
| Total Debt | 395K | 316.34M | 317.76M | 319.19M | 321.87M | 467.98M | 453.99M | 549.78M | 229.08M | 230.42M |
| Net Debt | -92.71M | 171.99M | 211.46M | 249.03M | 243.05M | -85.42M | -1.06B | -787.1M | -339.42M | -299.81M |
| Debt / Equity | 0.00x | - | - | - | - | 0.75x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -652.43x | -20.76x | -12.20x | -14.27x | -8.86x | -27.52x | -79.83x | -32.43x | -39.30x | -12.40x |
| Total Equity | 292.67M | -5.55M | -101.73M | -167.94M | -186.02M | 627.21M | -351.67M | -634.08M | -716.93M | -623.84M |
| Equity Growth % | 0.27% | -1.02% | -17.34% | -0.65% | -0.11% | 4.37% | -1.56% | -0.8% | -0.13% | 0.13% |
| Book Value per Share | 22.32 | -0.41 | -6.95 | -9.08 | -7.72 | 10.90 | -4.73 | -8.11 | -7.11 | -4.10 |
| Total Shareholders' Equity | 292.67M | -5.55M | -101.73M | -167.94M | -186.02M | 627.21M | -351.67M | -634.08M | -716.93M | -623.84M |
| Common Stock | 2.7M | 2.72M | 3.24M | 3.85M | 324K | 714K | 764K | 868K | 1.41M | 1.62M |
| Retained Earnings | -650.03M | -930M | -1.11B | -1.3B | -1.43B | -1.87B | -3.62B | -4.28B | -4.82B | -5.01B |
| Treasury Stock | -2.45M | -2.45M | -2.45M | -2.45M | -2.58M | -41.81M | -85.1M | -90.66M | -92.27M | -95.85M |
| Accumulated OCI | -9.12M | -11.81M | -8.62M | -11.19M | -12.51M | 7.02M | -1.35M | -6.38M | 2.72M | -22.56M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -126.09M | -255.47M | -138.7M | -184.82M | -136.62M | -42.54M | 322.95M | -415.94M | -713.97M | -87.26M |
| Operating CF Margin % | -3.48% | -16.64% | -4.45% | -5.39% | -7.32% | -1.9% | 1.63% | -0.26% | -1.28% | -0.13% |
| Operating CF Growth % | -0.88% | -1.03% | 0.46% | -0.33% | 0.26% | 0.69% | 8.59% | -2.29% | -0.72% | 0.88% |
| Net Income | -156.94M | -279.97M | -183.77M | -184.75M | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M | -187.5M |
| Depreciation & Amortization | 5.98M | 8.51M | 9.82M | 8.16M | 5.68M | 4.88M | 12.66M | 29.05M | 41.23M | 48.5M |
| Stock-Based Compensation | 13.43M | 19.16M | 19.81M | 18.31M | 17.05M | 128.03M | 183.63M | 130.3M | 85.36M | 48.15M |
| Deferred Taxes | 681K | 374K | 269K | -55K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.53M | 3.93M | 6.07M | -5.35M | -2.63M | 230.78M | 136.79M | 443.8M | 81.35M | -44.89M |
| Working Capital Changes | 7.22M | -7.47M | 9.11M | -21.14M | -24.02M | 12.02M | 1.73B | -361.15M | -376.84M | 48.48M |
| Change in Receivables | 6.25M | 2.07M | 0 | 1.21M | -4.2M | -422.69M | -192.26M | 249.17M | -274.44M | 354.09M |
| Change in Inventory | -8.04M | -1.98M | 0 | 0 | 0 | 0 | -600.33M | -477.8M | -74.46M | 12.91M |
| Change in Payables | 9.07M | -4.81M | 5.19M | -6.74M | 0 | 163.16M | 600.33M | 913.4M | -378.81M | -385.63M |
| Cash from Investing | -21.27M | 28.02M | 35.97M | 28.6M | 38.49M | -377.78M | 100.15M | -92.98M | -58.81M | -204.04M |
| Capital Expenditures | -18.29M | -18.21M | -4.19M | -1.37M | -1.86M | -54.62M | -57.49M | -92.98M | -58.81M | -14.64M |
| CapEx % of Revenue | 0.5% | 1.19% | 0.13% | 0.04% | 0.1% | 2.44% | 0.29% | 0.06% | 0.11% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -18.27M | -18.2M | -4.19M | -1.37M | 18.33M | 0 | -57.49M | 0 | 0 | 0 |
| Cash from Financing | 208.28M | 279.03M | 64.54M | 102.81M | 98.38M | 984.76M | 461.71M | 324.99M | 4.47M | 260.58M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 4.67M | -49.31M | 1.15M | 2.75M | 992K | 5.38M | 24.76M | -5.9M | -3.59M | 1.3M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -144.38M | -273.68M | -142.88M | -186.2M | -138.48M | -97.16M | 265.46M | -508.92M | -772.77M | -100.32M |
| FCF Margin % | -3.98% | -17.83% | -4.58% | -5.43% | -7.42% | -4.34% | 1.34% | -0.32% | -1.39% | -0.15% |
| FCF Growth % | -0.94% | -0.9% | 0.48% | -0.3% | 0.26% | 0.3% | 3.73% | -2.92% | -0.52% | 0.87% |
| FCF per Share | -11.01 | -20.21 | -9.76 | -10.07 | -5.75 | -1.69 | 3.57 | -6.51 | -7.67 | -0.66 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.91x | 0.75x | 1.00x | 1.05x | 0.10x | -0.19x | 0.63x | 1.31x | 0.47x |
| Interest Paid | 0 | 0 | 0 | 0 | 12.19M | 13.71M | 19.43M | 18.04M | 17.35M | 17.57M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 12.61M | 17.98M | 190K | 949K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -60.1% | -195.01% | - | - | - | -189.6% | -1265.72% | - | - | - |
| Return on Invested Capital (ROIC) | -59.22% | -110.17% | -93.27% | -136.71% | -130.94% | -104.38% | - | - | - | - |
| Gross Margin | -348.67% | -1449.79% | 100% | 100% | -510.02% | 100% | 100% | 43.55% | 38.21% | 70.28% |
| Net Margin | -432.93% | -1823.53% | -589.46% | -538.81% | -697.15% | -1868.23% | -882.55% | -41.15% | -97.97% | -27.49% |
| Debt / Equity | 0.00x | - | - | - | - | 0.75x | - | - | - | - |
| Interest Coverage | -652.43x | -20.76x | -12.20x | -14.27x | -8.86x | -27.52x | -79.83x | -32.43x | -39.30x | -12.40x |
| FCF Conversion | 0.80x | 0.91x | 0.75x | 1.00x | 1.05x | 0.10x | -0.19x | 0.63x | 1.31x | 0.47x |
| Revenue Growth | 18.24% | -57.65% | 103.06% | 9.98% | -45.57% | 19.97% | 782.53% | 709.26% | -65.2% | 22.61% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Royalties and Other | - | - | - | 197.58M | 43.99M | 24.99M | 491.95M |
| Royalties and Other Growth | - | - | - | - | -77.74% | -43.18% | 1868.35% |
| Product | - | - | - | - | 1.55B | 531.39M | 190.21M |
| Product Growth | - | - | - | - | - | -65.83% | -64.20% |
| Grant | 34.29M | 11.16M | 258.35M | 948.71M | 382.92M | 427.32M | - |
| Grant Growth | - | -67.45% | 2214.57% | 267.22% | -59.64% | 11.60% | - |
| Government Contract | - | 7.5M | 217.25M | - | - | - | - |
| Government Contract Growth | - | - | 2796.61% | - | - | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| UNITED STATES | - | - | - | - | - | - | 522.53M |
| UNITED STATES Growth | - | - | - | - | - | - | - |
| Europe | - | - | - | - | 823.54M | 268.36M | 96.14M |
| Europe Growth | - | - | - | - | - | -67.41% | -64.17% |
| the World | - | - | - | - | 536.94M | 233.07M | 59.02M |
| the World Growth | - | - | - | - | - | -56.59% | -74.68% |
| North America | - | - | - | - | - | - | 4.46M |
| North America Growth | - | - | - | - | - | - | - |
| North America | - | - | - | - | 194.48M | 29.96M | - |
| North America Growth | - | - | - | - | - | -84.60% | - |
Novavax, Inc. (NVAX) reported $1.06B in revenue for fiscal year 2024. This represents a 7148% increase from $14.7M in 2011.
Novavax, Inc. (NVAX) grew revenue by 22.6% over the past year. This is strong growth.
Yes, Novavax, Inc. (NVAX) is profitable, generating $341.7M in net income for fiscal year 2024 (-27.5% net margin).
Novavax, Inc. (NVAX) had negative free cash flow of $384.4M in fiscal year 2024, likely due to heavy capital investments.